Literature DB >> 23839861

Higher surgeon and hospital volume improves long-term survival after radical cystectomy.

Girish S Kulkarni1, David R Urbach, Peter C Austin, Neil E Fleshner, Andreas Laupacis.   

Abstract

BACKGROUND: Hospital and surgeon (provider) volume are associated with clinically significant outcomes for many types of surgery. Volume-outcome studies in patients undergoing radical cystectomy for bladder cancer have focused primarily on postoperative mortality. In the current study, the authors assessed the effect of cystectomy provider volume on long-term mortality.
METHODS: Using administrative databases, 2535 patients who underwent cystectomy by 199 surgeons in 90 hospitals in Ontario, Canada, between 1992 and 2004 were identified. The impact of provider volume on overall survival (OS) was assessed using Cox proportional hazards models fully adjusted for patient and tumor characteristics. Separate models were fit to examine the effect of surgeon and hospital volume. To confirm that the impact of volume on OS was independent of the effect of volume on short-term mortality, analyses were repeated excluding those patients experiencing postoperative deaths.
RESULTS: Of 2535 patients, 1796 (70.9%) died during the study period. Both higher hospital volume (hazards ratio [per unit increase in average annual number of procedures], 0.995; 95% confidence interval, 0.990-1.000 [P = .044]) and higher surgeon volume (hazards ratio, 0.984; 95% confidence interval, 0.975-0.994 [P = .002]) were found to be significantly associated with improved OS. Excluding post-operative deaths did not alter the results. Further analyses revealed that the benefit of high volume was attained by receiving care from either high-volume hospitals or high-volume surgeons.
CONCLUSIONS: High-volume providers were associated with improved long-term mortality rates compared with low-volume providers. This finding was independent of the effect of volume on perioperative mortality, suggesting that provider volume effects continue to manifest long after surgery.
Copyright © 2013 American Cancer Society.

Entities:  

Keywords:  bladder cancer; bladder neoplasm; cystectomy; outcomes; quality of health care

Mesh:

Year:  2013        PMID: 23839861     DOI: 10.1002/cncr.28235

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Confirming the volume-outcome relationship in bladder cancer: Now what?

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

2.  High hospital and surgeon volume and its impact on overall survival after radical cystectomy among patients with bladder cancer in Quebec.

Authors:  Fabiano Santos; Ahmed S Zakaria; Wassim Kassouf; Simon Tanguay; Armen Aprikian
Journal:  World J Urol       Date:  2014-12-04       Impact factor: 4.226

3.  Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Authors:  Girish S Kulkarni; Peter C Black; Srikala S Sridhar; Anil Kapoor; Alexandre R Zlotta; Bobby Shayegan; Ricardo A Rendon; Peter Chung; Theodorus van der Kwast; Nimira Alimohamed; Yves Fradet; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2019-01-31       Impact factor: 1.862

4.  Surgical subspecialization: escape route for surgeons or added benefit for patients?

Authors:  Meredith J Sorensen
Journal:  J Grad Med Educ       Date:  2014-06

5.  Confirmation de la relation entre le volume et les résultats des soins pour le cancer de la vessie : que faire maintenant ?

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

6.  Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice.

Authors:  Christopher M Booth
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

7.  National Trends in Oncologic Diagnostic Imaging.

Authors:  Andrew B Rosenkrantz; Laura Chaves Cerdas; Danny R Hughes; Michael P Recht; Sharyl J Nass; Hedvig Hricak
Journal:  J Am Coll Radiol       Date:  2020-07-05       Impact factor: 5.532

8.  Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Authors:  Wassim Kassouf; Armen Aprikian; Fred Saad; Rodney H Breau; Girish Kulkarni; David M Guttman; Ken Bagshaw; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Fadi Brimo; Peter Chung; Darrel Drachenberg; Yves Fradet; Niels Jacobsen; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Alex Zlotta; Neil Fleshner; D Robert Siemens; Peter C Black
Journal:  Can Urol Assoc J       Date:  2018-03-19       Impact factor: 1.862

9.  Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base.

Authors:  Matthew E Nielsen; Katherine Mallin; Mark A Weaver; Bryan Palis; Andrew Stewart; David P Winchester; Matthew I Milowsky
Journal:  BJU Int       Date:  2014-05-22       Impact factor: 5.588

10.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.